Lexicon Pharmaceuticals | LXRX - Zysk Brutto Na Sprzedaży





Zysk Brutto Na Sprzedaży Zmiana Data
Abbott USD 6.54B 625M 2025-12
Acadia Pharmaceuticals USD 257.76M 778K 2025-12
Agios Pharmaceuticals USD 18.09M 6.89M 2025-12
Akebia Therapeutics USD 47.28M 1.7M 2025-12
Alnylam Pharmaceuticals USD 829.31M 219.56M 2025-12
AstraZeneca USD 12.39B 5M 2025-12
BioMarin Pharmaceutical USD 713.01M 81.81M 2025-12
Coherus Biosciences USD 8.7M 853K 2025-12
Eli Lilly USD 14.59B 1.48B 2025-09
Esperion Therapeutics USD 140.59M 94.57M 2025-12
Halozyme Therapeutics USD 281.77M 2.41M 2025-09
Illumina USD 759M 26M 2025-12
Insmed USD 217.69M 106.25M 2025-12
Ironwood Pharmaceuticals USD 85.24M 44.1M 2025-06
J&J USD 16.6B 118M 2025-12
Lexicon Pharmaceuticals USD 5.29M 8.88M 2025-12
MacroGenics USD 31.11M 30.14M 2025-12
MannKind USD 78.31M 76.21M 2025-12
Merck USD 13.42B 431M 2025-09
Moderna USD 226M 583M 2025-12
Novartis USD 10.25B 570M 2025-12
PTC Therapeutics USD 148.38M 39.31M 2025-12
Puma Biotechnology USD 20.32M 24.85M 2024-09
Sarepta Therapeutics USD 43.55M 204.36M 2025-12
Thermo Fisher Scientific USD 4.64B 419M 2025-12
Ultragenyx Pharmaceutical USD 178M 46.06M 2025-12
United Therapeutics USD 315.5M 286.6M 2025-12
Vanda Pharmaceuticals USD 50.6M 5.5M 2024-12